Refocus Group, Inc. is a medical device company engaged in the research and development of treatments for human vision disorders. Our mission is to become the surgical standard of care for presbyopia. Refocus Group's latest product is the VisAbility™ Implant System, which is used in an innovative procedure known as the VisAbility™ Procedure. The implant is an investigational device and is not yet approved for sale or use in the United States or Canada. However, the product is currently approved for sale in the European Union.
Looking for a particular Refocus Group, Inc. employee's phone or email?
The Refocus Group, Inc. annual revenue was $5 million in 2026.
Dave Ozinga is the Vice President of Manufacturing Operations of Refocus Group, Inc..
2 people are employed at Refocus Group, Inc..
Refocus Group, Inc. is based in Dallas, Texas.
The NAICS codes for Refocus Group, Inc. are [33, 541, 54].
The SIC codes for Refocus Group, Inc. are [384, 38].